Literature DB >> 12734348

Extracellular matrix conditions T cells for adhesion to tissue interstitium.

Kimberly A Krivacic1, Alan D Levine.   

Abstract

The activation and differentiation of peripheral blood T cells (PBT) are known to correlate with increased surface expression and adhesive capacity of beta(1) integrins, which mediate adhesion to the extracellular matrix (ECM). However, little is known about the regulation of integrin expression, affinity, and avidity on tissue T cells after they are embedded in the interstitial ECM. In this study we show that tissue T cells, freshly isolated from their residence in the interstitial ECM of the intestinal lamina propria, express a distinct subset of functionally active integrins that contribute to enhanced adhesion to purified collagen, fibronectin, and cell-derived ECM when compared with freshly isolated, short term activated, and long term cultured PBT. Furthermore, integrin usage is distinct between circulating and tissue-derived T cells, in that lamina propria T cells prefer to bind to collagen, while PBT lymphoblasts choose fibronectin when presented with a complex, three-dimensional, cell-derived matrix. To identify the extrinsic factors that regulate the conversion from a nonadhesive PBT to highly adhesive tissue T cell, we demonstrate that activation of PBT in the presence of fibronectin or collagen rapidly generates a surface integrin expression profile, an integrin usage pattern, and adhesive capacity mirroring that of a tissue T cell. These results indicate that the tissue ECM microenvironment instructs newly arrived T cells for further interactions with the underlying matrix and thereby imprints them with a signature tissue adhesive phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734348     DOI: 10.4049/jimmunol.170.10.5034

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Roles of reactive oxygen species in CXCL8 and CCL2 expression in response to the 30-kDa antigen of Mycobacterium tuberculosis.

Authors:  Hye-Mi Lee; Dong-Min Shin; Kwang-Kyu Kim; Ji-Sook Lee; Tae-Hyun Paik; Eun-Kyeong Jo
Journal:  J Clin Immunol       Date:  2008-08-09       Impact factor: 8.317

2.  Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function.

Authors:  Steve Gendron; Marc Boisvert; Nizar Chetoui; Fawzi Aoudjit
Journal:  Immunology       Date:  2008-05-13       Impact factor: 7.397

3.  The Use of a Pure Native Collagen Dressing for Wound Bed Preparation Prior to Use of a Living Bi-layered Skin Substitute.

Authors:  Naz Wahab; Martha Roman; Debashish Chakravarthy; Tammy Luttrell
Journal:  J Am Coll Clin Wound Spec       Date:  2015-04-15

Review 4.  Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors.

Authors:  Ryan S Lane; Amanda W Lund
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

5.  Activation of Peripheral Blood CD4+ T-Cells in IBS is not Associated with Gastrointestinal or Psychological Symptoms.

Authors:  Yasmin Nasser; Carlene Petes; Celine Simmers; Lilian Basso; Christophe Altier; Katrina Gee; Stephen J Vanner
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

Review 6.  Natural Killer Cell Integrins and Their Functions in Tissue Residency.

Authors:  Michael J Shannon; Emily M Mace
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

7.  Astrocyte depletion alters extracellular matrix composition in the demyelinating phase of Theiler's murine encephalomyelitis.

Authors:  Lisa Allnoch; Eva Leitzen; Isabel Zdora; Wolfgang Baumgärtner; Florian Hansmann
Journal:  PLoS One       Date:  2022-06-17       Impact factor: 3.752

8.  Alpha2beta1 Integrin (VLA-2) Protects Activated Human Effector T Cells From Methotrexate-Induced Apoptosis.

Authors:  Amna Abderrazak; Mohammed-Amine El Azreq; Dalila Naci; Paul R Fortin; Fawzi Aoudjit
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.